Compare Kinder Morgan Inc (KMI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Kinder Morgan Inc trades at $33.53 (market cap $74.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Kinder Morgan Inc is far larger — about 14.8× Travere Therapeutics Inc. Common Stock's market cap, and Kinder Morgan Inc pays a 3.54% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KMI | TVTX | |
|---|---|---|
Market Cap | $74.26B | $5.02B |
Volume | 12,072,157 | 2,060,842 |
Sector | Energy | Health |
52-Week High | $34.31 | $67.52 |
52-Week Low | $25.84 | $26.79 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.31B | $5.15B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains solid fundamentals with $16.94B revenue, 19.31% net margin, and a $6B-$7B growth pipeline. Analyst consensus is mixed with 47% buy ratings and a $37.20 price target, while technical indicators show support at $33 and resistance at $34.
KMI offers income investors a compelling dividend yield with growth potential from natural gas infrastructure demand, though elevated debt levels and energy market volatility present risks. The stock's current valuation at 21.57 P/E appears reasonable given earnings growth trajectory and stable fee-based revenue model.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
